SPOTLIGHT: IDM Pharma outlines plans for Junovan


San Diego-based IDM Pharma confirmed plans to submit an NDA for Junovan as a therapy for osteosarcoma following a pre-NDA meeting with the FDA. Osteosarcoma is a bone cancer that occurs predominantly in adolescents and young adults. Release